{
    "eid": "2-s2.0-84941024465",
    "title": "Preserving the peritoneal membrane in long-term peritoneal dialysis patients",
    "cover-date": "2015-10-01",
    "subject-areas": [
        {
            "$": "Pharmacology",
            "@code": "3004"
        },
        {
            "$": "Pharmacology (medical)",
            "@code": "2736"
        }
    ],
    "keywords": [
        "fibrosis",
        "mesothelial cell",
        "peritoneal dialysis",
        "peritoneum",
        "therapeutics"
    ],
    "authors": [
        "P. Ditsawanon"
    ],
    "citedby-count": 19,
    "ref-count": 102,
    "ref-list": [
        "A Global Perspective",
        "Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease",
        "F1000Res",
        "Longitudinal changes in peritoneal kinetics: The effects of peritoneal dialysis and peritonitis",
        "Peritoneal fibrosis intervention",
        "Factors contributing to peritoneal tissue remodeling in peritoneal dialysis",
        "Inflammation and the peritoneal membrane: Causes and impact on structure and function during peritoneal dialysis",
        "Int J Nephrol",
        "Nolph and Gokal's Textbook of Peritoneal Dialysis",
        "Peritoneal fibrosis - Future prevention strategies",
        "Nolph and Gokal's Textbook of Peritoneal Dialysis",
        "Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: Pathologic significance and potential therapeutic interventions",
        "Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells",
        "Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury",
        "Peritoneal membrane structural and functional changes during peritoneal dialysis",
        "New insights in the molecular mechanisms regulating peritoneal permeability",
        "Mechanisms and interventions in peritoneal fibrosis",
        "Vascular endothelial growth factor receptor-3 is a novel target to improve net ultrafiltration in methylglyoxal-induced peritoneal injury",
        "A pathogenetic role for endothelin-1 in peritoneal dialysis-associated fibrosis",
        "Physiological approaches to increase biocompatibility of peritoneal dialysis.",
        "Chemistry of glucose and biochemical pathways of biological interest",
        "Studying the effects of new peritoneal dialysis solutions on the peritoneum",
        "Toward better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes",
        "The clinical usefulness of peritoneal dialysis fluids with neural pH and low glucose degradation product concentration: An open randomized prospective trial",
        "The Euro-Balance Trial: The effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane",
        "The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability",
        "Low-GDP peritoneal dialysis fluid ('balance') has less impact in vitro and ex vivo on epithelial-to-mesenchymal transition (EMT) of mesothelial cells than a standard fluid",
        "Effects of low-glucose degradation product solution on peritoneal membrane characteristics in peritoneal dialysis patients: A 3-year follow-up study",
        "The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: The balANZ trial",
        "Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes",
        "Biocompatible dialysis fluids for peritoneal dialysis",
        "Effect of biocompatible peritoneal dialysis solution on residual renal function: A systematic review of randomized controlled trials",
        "CAPD with an amino acid dialysis solution: A long-term, cross-over study",
        "Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious",
        "An update on peritoneal dialysis solutions",
        "Recommendations for the use of icodextrin in peritoneal dialysis patients",
        "A randomized multicenter clinical trial comparing isosmolar Icodextrin with hyperosmolar glucose solutions in CAPD",
        "Icodextrin metabolites in peritoneal dialysis",
        "Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studied ex vivo",
        "Icodextrin improves the fluid status of peritoneal dialysis patients: Results of a double-blind randomized controlled trial",
        "Randomized controlled trial of icodextrin versus glucose containing peritoneal dialysis fluid",
        "Efficacy and safety of a 7.5% Icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis",
        "Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: A Randomized controlled trial",
        "Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients",
        "TGF-\u03b2 in kidney fibrosis: A target for gene therapy",
        "Inhibition of the effect of high glucose on the expression of Smad in human peritoneal mesothelial cells",
        "Valsartan decreases TGF-\u03b21 production and protects against chlorhexidine digluconate-induced liver peritoneal fibrosis in rats",
        "Effect of valsartan versus lisinopril on peritoneal sclerosis in rats",
        "Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum.",
        "Aliskiren prevents the toxic effects of peritoneal dialysis fluids during chronic dialysis in rats",
        "Aliskiren ameliorates chlorhexidine digluconate-induced peritoneal fibrosis in ratsARTICLE",
        "Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model",
        "Impact of ace inhibitors and all receptor blockers on peritoneal membrane transport characteristics in long-term peritoneal dialysis patients",
        "Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients: Original Article",
        "Influence of renin-angiotensin-aldosterone system-blocking drugs on peritoneal membrane in peritoneal dialysis patients",
        "A positive effect of AII inhibitors on peritoneal membrane function in long-term PD patients",
        "Effects of spironolactone on residual renal function and peritoneal function in peritoneal dialysis patients",
        "Long-term effects of spironolactone in peritoneal dialysis patients",
        "Medical Biochemistry",
        "Altering peritoneal membrane function: Removing the GAG",
        "Pathophysiology of the peritoneal membrane during peritoneal dialysis: The role of hyaluronan",
        "Effect of haluronan-supplemented dialysate on in vitro function of human peritoneal mesothelial cells",
        "Agents preventing decrease in ultrafiltration in a rat model with peritoneal hyperpermeability",
        "Low molecular weight heparin improves peritoneal ultrafiltration and blocks complement and coagulation",
        "Intraperitoneal heparin reduces peritoneal permeability and increases ultrafiltration in peritoneal dialysis patients",
        "Glycosaminoglycans prevent the functional and morphological peritoneal derangement in an experimental model of peritoneal fibrosis",
        "Anti-inflammatory effect of sulodexide during acute peritonitis in rats",
        "Oral supplementation with sulodexide inhibits neo-angiogenesis in a rat model of peritoneal perfusion",
        "Use of glycosaminoglycans to increase efficiency of long-term continuous peritoneal dialysis",
        "Effect of oral treatment with the glycosaminoglycan sulodexide on peritoneal transport in CAPD patients",
        "Carnitine. Metabolism and functions",
        "Prevention of peritoneal sclerosis: A new proposal to substitute glucose with carnitine dialysis solution (biocompatibility testing in vitro and in rabbits)",
        "L-Carnitine is an osmotic agent suitable for peritoneal dialysis",
        "Evaluation of taurine as in osmotic agent for peritoneal dialysis solution",
        "PPAR-\u03b3 agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage",
        "Troglitazone inhibits synthesis of transforming growth factor-\u03b21 and reduces matrix production in human peritoneal mesothelial cells",
        "Pioglitazone inhibits high glucose-induced synthesis of extracellular matrix by NF-\u03baB and AP-1 pathways in rat peritoneal mesothelial cells",
        "Hormones-Cytokines-Cignaling: Dipyridamole inhibits TGF-\u03b2-induced collagen gene expression in human peritoneal mesothelial cells",
        "Dipyridamole inhibits human peritoneal mesothelial cell proliferation in vitro and attenuates rat peritoneal fibrosis in vivo",
        "A selective cyclooxygenase-2 inhibitor decreases transforming growth factor-\u03b21 synthesis and matrix production in human peritoneal mesothelial cells"
    ],
    "affiliation": {
        "affiliation-city": "Bangkok",
        "affilname": "Chulalongkorn University",
        "affiliation-country": "Thailand"
    },
    "funding": []
}